Goldman picks China healthcare stocks for a post-AI trade

Goldman Sachs said Chinese companies it tracks delivered 24% year-over-year Q2 earnings growth, the fastest pace in five years and up from 6% in Q1, while nearly half of MSCI China constituents beat estimates. AI-related names drove much of the improvement, but Goldman sees potential upside in downstream AI applications and healthcare, screening for companies with over 15% annual earnings growth through 2027 and median EPS estimate increases of 7% in the past month. Goldman remains comparatively cautious on the broader market, forecasting 8% MSCI China earnings growth this year versus 17% consensus.

Analysis

The actionable signal is not the aggregate China earnings print but the dispersion between crowded AI supply-chain exposures and application-layer beneficiaries. China biotech offers operating leverage to improving reimbursement, licensing income and commercialization scale, while its valuation is less dependent on sustaining elevated hardware capex. Innovent (1801 HK), CSPC (1093 HK) and Hansoh (3692 HK) should also benefit from a rotation by Hong Kong growth funds seeking earnings revisions without adding to semiconductor-factor concentration; BeOne (ONC US / 6160 HK) is the higher-beta oncology expression but carries materially greater clinical and U.S.-China policy sensitivity.

The near-term risk is that estimate upgrades remain broker-model driven rather than verified by product sales, NRDL reimbursement outcomes, or margins. In particular, pipeline-led earnings forecasts can reverse sharply on trial data, pricing negotiations, or slower hospital utilization; a broad China risk-off move would likely swamp company-specific revision momentum. Over 1-3 months, the catalyst is third-quarter guidance and further consensus upgrades; over 6-18 months, the differentiator will be whether domestic innovators convert approvals into profitable commercial franchises rather than merely gain market share through price cuts.

Contrarian view: the market may be underpricing a factor rotation within China rather than a durable index-level rerating. If broad MSCI China earnings fail to close the gap with optimistic consensus expectations, benchmark-heavy vehicles tied to MSCI (MSCI) should see limited fundamental upside, while selective healthcare can still outperform. GS is a sentiment and research-distribution beneficiary rather than a clean earnings beneficiary; there is no standalone trade in GS from this information.

Key Decisions for Investors

• Initiate a 3-month equal-weight long basket in 1801 HK, 1093 HK and 3692 HK, sized at 50-75 bps total initially. Target 15-20% relative upside versus the Hang Seng China Enterprises Index if revisions translate into quarterly execution; cut if combined FY earnings consensus falls more than 5% or reimbursement/pricing actions impair gross-margin guidance.
• Express the rotation as long the China healthcare basket / short Hang Seng TECH ETF (3067 HK) in equal beta through the next earnings season. This isolates the application-versus-AI-hardware crowding thesis; exit if AI-capex guidance accelerates again or the healthcare basket underperforms by 10% on unchanged estimates.
• Use ONC US or 6160 HK only as a catalyst-driven satellite position, not a core China allocation. Enter after confirmation of quarterly commercial momentum or a positive regulatory/clinical catalyst; size small because a single trial, label, or geopolitical development can dominate earnings revisions.
• Do not add broad MSCI China beta solely on the earnings narrative. Set an alert for aggregate forward EPS revisions turning positive and for China healthcare relative strength versus 3067 HK; absent both, treat the opportunity as stock selection rather than an index trade.